India's ambition to eliminate visceral leishmaniasis.
Talha
T
Burki
D000666:Amphotericin B / Q000627:therapeutic use*; D000981:Antiprotozoal Agents / Q000627:therapeutic use*; D006801:Humans; D015994:Incidence; D007194:India / Q000453:epidemiology; D007898:Leishmaniasis, Visceral / Q000453:epidemiology / Q000517:prevention & control*
D000981:Antiprotozoal Agents; C068538:liposomal amphotericin B; D000666:Amphotericin B